* 4.2.1 has another serious or chronic medical or psychiatric condition that contributes to substantial physical or emotional disability that would detract from participating in the planned study. * 4.2.2 taking chronic medications that would interfere with cognitive functioning such as medications for sleep, anxiety, narcotics for pain, use of illicit medical foods or cannabis. * 4.2.3 participants may not be receiving any other investigational agents. * 4.2.4 history of allergic reactions attributed to compounds of similar chemical or biologic composition to oxaloacetate. * 4.2.5 uncontrolled intercurrent illness including, but not limited to, ongoing or active infection of covid-19 or other virus, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * 4.2.6 pregnant or breast-feeding women are excluded from this study because the safety of oxaloacetate in this setting is unknown. a pregnancy test will be performed on all women with an intact uterus and ovaries who are not determined to be postmenopausal, as described in section 4.1.7.

* 4.2.1 has another serious or chronic medical or psychiatric condition that contributes to substantial physical or emotional disability that would detract from participating in the planned study. * 4.2.2 taking chronic medications that would interfere with cognitive functioning such as medications for sleep, anxiety, narcotics for pain, use of illicit medical foods or cannabis. * 4.2.3 participants may not be receiving any other investigational agents. * 4.2.4 history of allergic reactions attributed to compounds of similar chemical or biologic composition to oxaloacetate. * 4.2.5 uncontrolled intercurrent illness including, but not limited to, ongoing or active infection of covid-19 or other virus, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * 4.2.6 pregnant or breast-feeding women are excluded from this study because the safety of oxaloacetate in this setting is unknown. a pregnancy test will be performed on all women with an intact uterus and ovaries who are not determined to be postmenopausal, as described in section 4.1.7.

- 4.2.1 has another serious or chronic medical or psychiatric condition that contributes to substantial physical or emotional disability that would detract from participating in the planned study. - 4.2.2 taking chronic medications that would interfere with cognitive functioning such as medications for sleep, anxiety, narcotics for pain, use of illicit medical foods or cannabis. - 4.2.3 participants may not be receiving any other investigational agents. - 4.2.4 history of allergic reactions attributed to compounds of similar chemical or biologic composition to oxaloacetate. - 4.2.5 uncontrolled intercurrent illness including, but not limited to, ongoing or active infection of covid-19 or other virus, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. - 4.2.6 pregnant or breast-feeding women are excluded from this study because the safety of oxaloacetate in this setting is unknown. a pregnancy test will be performed on all women with an intact uterus and ovaries who are not determined to be postmenopausal, as described in section 4.1.7.

- 4.2.1 has another serious or chronic medical or psychiatric condition that contributes to substantial physical or emotional disability that would detract from participating in the planned study. - 4.2.2 taking chronic medications that would interfere with cognitive functioning such as medications for sleep, anxiety, narcotics for pain, use of illicit medical foods or cannabis. - 4.2.3 participants may not be receiving any other investigational agents. - 4.2.4 history of allergic reactions attributed to compounds of similar chemical or biologic composition to oxaloacetate. - 4.2.5 uncontrolled intercurrent illness including, but not limited to, ongoing or active infection of covid-19 or other virus, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. - 4.2.6 pregnant or breast-feeding women are excluded from this study because the safety of oxaloacetate in this setting is unknown. a pregnancy test will be performed on all women with an intact uterus and ovaries who are not determined to be postmenopausal, as described in section 4.1.7.